Child psychiatry, disruptive behaviour disorders, attention deficit hyperactivity disorders (ADHD), day treatment and transcultural child psychiatry.

Natalie Grizenko, MD, FRCPC is active as a clinician researcher, teacher and administrator. She has been medical chief of the Severe Disruptive Behavior Disorders Program since 1988. From 1996 to 2001, she was the director of professional and hospital services at the Douglas Institute and was involved in the restructuring of ultraspecialized programs and the development of a community-based model of psychiatric services.

Since October 2001, Natalie Grizenko has assumed the position of medical director of the Child and Adolescent Psychiatry Program, with the tripartite mandate of integrating research, teaching and clinical excellence throughout the program. She has also been very much involved in clinical teaching and research assuming the role of postgraduate training coordinator in child psychiatry at the Douglas Institute from 1991 to 2001. She was also co-director of the Child Psychopathology Axis of the Douglas Research Center.

Natalie Grizenko has conducted research in day treatment effectiveness, risk and protective factors in children, transcultural child psychiatry, effectiveness of social skills training, pharmacogenetics of ADHD (with Ridha Joober, MD, PhD) and prenatal/postnatal risk factors in ADHD (with Leila Ben-Amor, MD, MSc). She has received (as PI or Co-PI) over 51 grants totalling $3,011,921. She has supervised 80 psychiatry residents, medical research students, Masters and Ph.D. students. Natalie Grizenko has published 53 papers and book chapters, and has written 2 books.

Douglas Institute Bond Pavilion Room Z-2115 6875, boulevard LaSalle Montreal (Quebec) H4H 1R3

Phone : 514 761-6131 ext.: 2053 Fax : 514 762-3041